The Magazine for Sleep Professionals
Saturday, May 23, 2026
Sleep.ai announced findings from a peer-reviewed study led by Washington State University, in collaboration with the University of Washington, exploring sleep patterns in people with chronic insomnia. It is the longest known objective, real-world characterization of objective sleep in chronic insomnia. Published in JMIR Formative Research, the study tracked 112 adults […]
Nihon Kohden announced it is expanding the reach of NomadAir® with Connect — its established at-home sleep apnea diagnostic system — into dental sleep medicine. The company will feature the solution at the American Academy of Dental Sleep Medicine (AADSM) Annual Meeting, taking place May 1–3 in Chicago (Booth 408). The expansion […]
Nexalin Technology, Inc. announced the online publication of a peer-reviewed study in Psychotherapy and Psychosomatics reporting significant clinical improvement and measurable brain-network modulation in patients with chronic insomnia treated with the Company’s high-power 15 mA, 77.5 Hz stimulation approach. The paper was published online on April 20, 2026. The study, titled: “Modulating […]
Narcolepsy Network, a national non-profit organization for people living with narcolepsy and idiopathic hypersomnia (IH), is pleased to announce the appointment of Liz Burgess as its new Executive Director. Liz has dedicated her career to mission-driven leadership, serving for more than 20 years as an Executive Director of a diverse range of nonprofit […]
Dr. Funke Afolabi-Brown, a board-certified sleep medicine physician and founder of The Restful Sleep Place, is expanding her national reach through a series of initiatives, including a new role as sleep expert for the parenting platform HumanUp, a feature in Sleep Review Magazine, and the launch of a comprehensive online insomnia program […]
Alkermes plc presents new data from the Vibrance-1 phase 2 study evaluating alixorexton in patients with narcolepsy type 1 (NT1) at the American Academy of Neurology (AAN) 2026 Annual Meeting, taking place April 18-22, 2026 in Chicago. Alixorexton is a novel, investigational, oral, selective orexin 2 receptor (OX2R) agonist in development for the treatment […]
Narcolepsy Network, a national non-profit organization for people living with narcolepsy and idiopathic hypersomnia (IH), is proud to announce the appointment of Desireé Gorbea-Finalet and Mike Heil to its Board of Directors. Both new members live with narcolepsy and will bring fresh perspectives and deep advocacy experience to the organization as it prepares to […]
Mount Sinai researchers have created an analytic tool using machine learning that can predict cardiovascular disease risk in millions of patients with obstructive sleep apnea, a serious sleep disorder, according to findings recently published in Communications Medicine. The team said their study is the first to provide estimates of whether […]
Alkermes plc, announced the initiation of the Brilliance Studies, a phase 3 program evaluating the safety and efficacy of alixorexton compared to placebo in adults with narcolepsy type 1 (NT1) and narcolepsy type 2 (NT2). Alixorexton is the company’s novel, investigational, oral, selective orexin 2 receptor (OX2R) agonist in development […]
Eisai Inc. announced today that screening for global Study E2086-G000-202 (Study 202) to assess the efficacy, safety and tolerability of E2086, a novel selective orexin-2 receptor, is now registered on ClinicalTrials.gov as NCT07493265. Study sites are also planned for Canada, China, Europe, Japan, and South Korea. Study 202 is a three-period, […]
